AU2017370003B2 - 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine- 2,4-dione for treating nonalcoholic fatty liver disease - Google Patents

5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine- 2,4-dione for treating nonalcoholic fatty liver disease Download PDF

Info

Publication number
AU2017370003B2
AU2017370003B2 AU2017370003A AU2017370003A AU2017370003B2 AU 2017370003 B2 AU2017370003 B2 AU 2017370003B2 AU 2017370003 A AU2017370003 A AU 2017370003A AU 2017370003 A AU2017370003 A AU 2017370003A AU 2017370003 B2 AU2017370003 B2 AU 2017370003B2
Authority
AU
Australia
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
thiazolidine
hydroxyethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017370003A
Other languages
English (en)
Other versions
AU2017370003A1 (en
Inventor
Marc Martinell Pedemonte
Maria Pilar Pizcueta Lalanza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Minoryx Therapeutics SL
Original Assignee
Minoryx Therapeutics SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minoryx Therapeutics SL filed Critical Minoryx Therapeutics SL
Publication of AU2017370003A1 publication Critical patent/AU2017370003A1/en
Application granted granted Critical
Publication of AU2017370003B2 publication Critical patent/AU2017370003B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2017370003A 2016-12-01 2017-12-01 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine- 2,4-dione for treating nonalcoholic fatty liver disease Ceased AU2017370003B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16382584 2016-12-01
EP16382584.7 2016-12-01
PCT/IB2017/057587 WO2018100557A1 (en) 2016-12-01 2017-12-01 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine- 2,4-dione for treating nonalcoholic fatty liver disease

Publications (2)

Publication Number Publication Date
AU2017370003A1 AU2017370003A1 (en) 2019-06-06
AU2017370003B2 true AU2017370003B2 (en) 2023-04-13

Family

ID=57517838

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017370003A Ceased AU2017370003B2 (en) 2016-12-01 2017-12-01 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine- 2,4-dione for treating nonalcoholic fatty liver disease

Country Status (20)

Country Link
US (1) US11938122B2 (enExample)
EP (1) EP3548026B1 (enExample)
JP (1) JP7040798B2 (enExample)
KR (1) KR102595034B1 (enExample)
CN (1) CN110022877B (enExample)
AU (1) AU2017370003B2 (enExample)
BR (1) BR112019011334A2 (enExample)
CA (1) CA3044364A1 (enExample)
CY (1) CY1124116T1 (enExample)
DK (1) DK3548026T3 (enExample)
EA (1) EA201991304A1 (enExample)
ES (1) ES2867300T3 (enExample)
HR (1) HRP20210576T1 (enExample)
HU (1) HUE054346T2 (enExample)
LT (1) LT3548026T (enExample)
MX (1) MX379710B (enExample)
PL (1) PL3548026T3 (enExample)
PT (1) PT3548026T (enExample)
SI (1) SI3548026T1 (enExample)
WO (1) WO2018100557A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017370003B2 (en) 2016-12-01 2023-04-13 Minoryx Therapeutics S.L. 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine- 2,4-dione for treating nonalcoholic fatty liver disease
SI3801515T1 (sl) 2018-06-06 2025-07-31 Minoryx Therapeutics S.L. 5-[[4-[2-[5-(1-hidroksietil)piridin-2-il]etoksi]fenil]metil]-1,3-tiazolidin-2,4-dion in soli za uporabo pri zdravljenju mitohondrijske bolezni
AU2021265345A1 (en) 2020-04-30 2022-12-08 Minoryx Therapeutics S.L. Leriglitazone for treating lung inflammation and interstitial lung disease
EP4642456A1 (en) 2022-12-28 2025-11-05 Minoryx Therapeutics S.L. Optimized dosing of leriglitazone
WO2024231881A2 (en) 2023-05-09 2024-11-14 Minoryx Therapeutics S.L. Polymorphic forms and formulations of leriglitazone

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015150476A1 (en) * 2014-04-02 2015-10-08 Minoryx Therapeutics S.L. 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT68370A (en) * 1991-04-11 1995-06-28 Takeda Chemical Industries Ltd Thiazolidine derivatives, pharmaceutical compositions containing them and process for their production
US5441971A (en) 1991-04-11 1995-08-15 The Upjohn Company Thiazolidinedione derivatives, production and use thereof
AU4104593A (en) 1992-05-05 1993-11-29 Upjohn Company, The A process for producing pioglitazone metabolite
US5952509A (en) 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
US6191154B1 (en) 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
WO2003055485A1 (en) 2001-12-21 2003-07-10 Smithkline Beecham Corporation Dosing regimen for ppar-gamma activators
US8993773B2 (en) 2002-07-16 2015-03-31 Cadila Healthcare Limited Process to prepare pioglitazone via several novel intermediates
GB0510469D0 (en) 2005-05-23 2005-06-29 Leuven K U Res & Dev Insulin sensitization to slow down pubertal tempo and to augment pubertal growth
ES2397944T3 (es) 2006-03-16 2013-03-12 Metabolic Solutions Development Company Llc Análogos de tiazolidindiona
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
US8895537B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating cardiovascular diseases
US20150224120A1 (en) 2011-09-14 2015-08-13 Catherine Clelland Compositions and methods for treating hyperprolinemia-associated mental disorders
US8865747B2 (en) 2012-03-23 2014-10-21 Fundació Institute D'Investigació Biomėdica de Bellvitge (IDIBELL) Pioglitazone for use in the treatment of adrenoleukodystrophy
US20140178456A1 (en) 2012-08-30 2014-06-26 Udaya Sankar Devanaboyina Methods and compositions for treating type 2 diabetes and related conditions
JP6800013B2 (ja) 2013-03-14 2020-12-16 ポクセル・ソシエテ・アノニムＰｏｘｅｌ ＳＡ 重水素化２，４−チアゾリジンジオン及び治療方法
EP3094328B1 (en) 2014-01-15 2020-08-19 Poxel SA Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
AU2017370003B2 (en) 2016-12-01 2023-04-13 Minoryx Therapeutics S.L. 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine- 2,4-dione for treating nonalcoholic fatty liver disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015150476A1 (en) * 2014-04-02 2015-10-08 Minoryx Therapeutics S.L. 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KAWAGUCHI-SUZUKI M et al. "validated liquid chromatography tandem mass spec. method for determination of pioglitazone, hydroxypioglitazone, and ketopioglitazone in human plasma", J Chromatogr B Biomed Sci Appl, (2014), vol. 969, pp 219-223. *

Also Published As

Publication number Publication date
PL3548026T3 (pl) 2021-08-23
PT3548026T (pt) 2021-04-22
BR112019011334A2 (pt) 2019-10-15
EA201991304A1 (ru) 2019-12-30
CA3044364A1 (en) 2018-06-07
HRP20210576T1 (hr) 2021-05-28
LT3548026T (lt) 2021-05-25
CY1124116T1 (el) 2022-05-27
CN110022877A (zh) 2019-07-16
MX2019006066A (es) 2019-09-10
WO2018100557A1 (en) 2018-06-07
SI3548026T1 (sl) 2021-07-30
US11938122B2 (en) 2024-03-26
AU2017370003A1 (en) 2019-06-06
JP2020500868A (ja) 2020-01-16
KR102595034B1 (ko) 2023-10-26
EP3548026A1 (en) 2019-10-09
KR20190086766A (ko) 2019-07-23
HUE054346T2 (hu) 2021-08-30
CN110022877B (zh) 2023-06-23
US20200093812A1 (en) 2020-03-26
MX379710B (es) 2025-03-11
ES2867300T3 (es) 2021-10-20
JP7040798B2 (ja) 2022-03-23
EP3548026B1 (en) 2021-01-20
DK3548026T3 (da) 2021-04-19

Similar Documents

Publication Publication Date Title
AU2017370003B2 (en) 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine- 2,4-dione for treating nonalcoholic fatty liver disease
JP5249388B2 (ja) 糖尿病の治療及び予防のためのフタリド誘導体の使用
US20180117026A1 (en) Combination therapy using enantiopure, oxy-substituted, deuterium-enriched 5-(benzyl)-5-deutero-thiazolidine-2,4-diones for treatment of medical disorders
WO2018167103A1 (en) Pharmaceutical compositions for combination therapy
CN103998035A (zh) 包含格列酮和nrf2激活剂的药物组合物
JP5302900B2 (ja) 脂肪性肝疾患の治療用医薬組成物
JP2022050572A (ja) 高血糖症を処置する方法
JP7549344B2 (ja) 治療有効量の５－［［４－［２－［５－（１－ヒドロキシエチル）ピリジン－２－イル］エトキシ］フェニル］メチル］－１，３－チアゾリジン－２，４－ジオンを投与する方法
JP5679458B2 (ja) 内臓脂肪重量の低下剤
CA3102584A1 (en) Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts
EP3801515B1 (en) 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases
KR102784482B1 (ko) 신경퇴행성 질환 및/또는 그것의 임상적 상태를 억제 및/또는 치료하기 위한 조성물 및 방법
HK40014768B (en) 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]ph-enyl]methyl]-1,3-thiazolidine-2,4-dione for treating nonalcoholic fatty liver disease
HK40014768A (en) 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]ph-enyl]methyl]-1,3-thiazolidine-2,4-dione for treating nonalcoholic fatty liver disease
CN1726016A (zh) 阿尔茨海默氏病的预防和治疗
HK40012325A (en) 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine- 2,4-dione for treating nonalcoholic fatty liver disease
EP2412705A1 (en) Novel therapeutic agent for cognitive impairment
KR102896709B1 (ko) 신경 변성 질환의 예방 또는 치료약
EA040395B1 (ru) Применение 5-[[4-[2-[5-(1-гидроксиэтил)пиридин-2-ил]этокси]фенил]метил]-1,3-тиазолидин-2,4-диона или его фармацевтически приемлемой соли для лечения неалкогольной жировой болезни печени и способ лечения или предупреждения неалкогольной жировой болезни печени
JP2011001296A (ja) インスリン分泌促進剤
HK1254471B (zh) (r)-(+)-维拉帕米用於治疗高血糖的用途及其药学组合物
HK1126125A (en) Remedy for diabetic

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired